alexa Audit Assessing Omalizumab Treatment For Chronic Spontaneous Urticaria To NICE Guidelines | 71421
ISSN: 2155-6121

Journal of Allergy & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

11th International Conference on ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY

Tiffany Lau and Helen Bourne
Newcastle Medical School, UK
Dept. Immunology & Allergy, Newcastle-Upon-Tyne Hospitals Trust, UK
Posters & Accepted Abstracts: J Allergy Ther
DOI: 10.4172/2155-6121-C1-006
Abstract
Background: Chronic spontaneous urticaria (CSU) is an autoimmune skin disease defined by recurrent hives and angioedema over 6 weeks with no identifiable triggers. Omalizumab, a recombinant humanised monoclonal antibody, is approved by NICE as an add on therapy for CSU in patients over 12 years since 2015. Objectives: To examine how Omalizumab treatment for CSU meets standards set by NICE guidelines TA339. Method: A retrospective study of 37 patients who commenced their first course of six monthly subcutaneous injections between July 2015-January 2017 at the Regional Immunology and Allergy Unit, Newcastle-Upon-Tyne Hospitals Trust were identified on the department database. 9 patients who have not completed 6 doses were excluded from the treatment part of the analysis. Results: Of the 37 patients (age range 19-82, average 48, Female/Male: 33:4) 100% have no response to antihistamine and montelukast documented and 87% have a significant objective score >28 completed. Of the 36% who did not respond to treatment at the 4th dose- 20% stopped treatment appropriately, 50% did not stop treatment, 20% were not recorded and 10% stopped from adverse reactions. Of those who continued to finish 6 doses 80% stopped while 20% did not stop. Conclusion: Pre injection standards and treatment stopped after 6 doses were met well. Non-responders did not stop treatment after the 4th dose due to adjustments made to disease flares, other immunosuppressant medications taken during treatment and extended gaps between doses.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7